The RAS-mitogen-activated protein kinase (MAPK) signaling pathway has a central role in regulating the proliferation and survival of both normal and tumor cells. This pathway has been 1 focus area for the development of anticancer drugs, resulting in several compounds, primarily kinase inhibitors, in clinical testing. The authors have undertaken a cell-based, highthroughput screen using a novel ERF1 Redistribution ® assay to identify compounds that modulate the signaling pathway. The hit compounds were subsequently tested for activity in a functional cell proliferation assay designed to selectively detect compounds inhibiting the proliferation of MAPK pathway-dependent cancer cells. The authors report the identification of 2 cell membrane-permeable compounds that exhibit activity in the ERF1 Redistribution ® assay and selectively inhibit proliferation of MAPK pathway-dependent malignant melanoma cells at similar potencies (IC 50 = < 5 µM). These compounds have drug-like structures and are negative in RAF, MEK, and ERK in vitro kinase assays. Drugs belonging to these compound classes may prove useful for treating cancers caused by excessive MAPK pathway signaling. The results also show that cell-based, high-content Redistribution ® screens can detect compounds with different modes of action and reveal novel targets in a pathway known to be disease relevant. 1 The pathway is deregulated in various cancer types, and pathway-associated proteins are important targets in cancer drug discovery. Overexpression or mutations in receptor tyrosine kinases (RTKs) that result in excessive pathway activation are common in various types of carcinomas, and approximately 50% of several cancers, especially melanoma and colorectal and pancreatic cancers, exhibit aberrant MAPK pathway signaling.
T HE RAS-MITOGEN-ACTIVATED PROTEIN KINASE (MAPK)
signaling pathway is a major mitogenic pathway that links extracellular signals with cell proliferation and differentiation. 1 The pathway is deregulated in various cancer types, and pathway-associated proteins are important targets in cancer drug discovery. Overexpression or mutations in receptor tyrosine kinases (RTKs) that result in excessive pathway activation are common in various types of carcinomas, and approximately 50% of several cancers, especially melanoma and colorectal and pancreatic cancers, exhibit aberrant MAPK pathway signaling. [2] [3] [4] The MAPK pathway is activated by various growth factors that bind to RTKs, resulting in the activation of the RAS proteins. These proteins are GTPases that, when active, form a complex with RAF protein kinases. 5 This complex translocates to the plasma membrane where the RAF proteins subsequently activate MEK proteins. 5 The downstream MEK1 and 2 proteins are dual-specificity protein kinases and constitute a focal point in the pathway because the kinases ERK1 and 2 (also named p44 and p42 MAPKs) are the only identified MEK substrates. Inactive ERK proteins are sequestered in the cytoplasm by the MEK kinases. Activated MEK1/2 release ERK1/2 from their anchorage in the cytoplasm by phosphorylating ERK1/2 on tyrosine and threonine residues. 1, 6 Activated ERK proteins phosphorylate multiple downstream effectors and also move into the nucleus to regulate gene expression by phosphorylating certain transcription factors. 7, 8 As a result of stimulating these transcriptional regulators, key cell cycle regulatory proteins are expressed, which enable the cell to progress through the G1 phase of the cell cycle. 9 In the nucleus, ERK1/2 is inactivated by the MAPK phosphatases (MKPs). [10] [11] [12] The Ets domain transcriptional repressor ERF1 is a ubiquitously expressed distal target of the MAPK signaling pathway. Among the Ets family, nuclear ERF1 is unique because ERKdependent phosphorylation of ERF1 controls the activity of ERF1 by modulating its subcellular localization rather than by controlling its inherent transcriptional activity. 13, 14 Upon mitogenic stimulation, ERF1 is immediately phosphorylated by ERK and exported to the cytoplasm. Hence, inactivation of the MAPK pathway can be monitored by measuring the nuclear retention of ERF1.
expressing Rev-EGFP were FACS sorted to establish BHK PS1883 GS. The cells were cultured in a humidified incubator at 37 °C and 5% CO 2 and were passaged twice weekly by resuspension using 0.25% trypsin/0.53 mM EDTA solution (Invitrogen). All cell lines tested negative for Mycoplasma. The human cell lines (U2OS and T24) have been authenticated by multiplex PCR performed at DSMZ (Braunschweig, Germany).
ERF1 Redistribution ® assay
For use in the 384-well format screening assay, T24 ps 2087 GS cl. 1D3 cells were seeded at a density of 1500 cells per well in collagen-coated (Sigma, Sigma-Aldrich, St. Louis, MO) black 384-well plates (Corning Incorporated Life Sciences, Acton, MA) and incubated overnight (O/N) at 37 °C in a CO 2 incubator. The screening assay was initiated by adding 10.0 µM library compound prepared as a 125× concentrated solution in assay buffer (DMEM containing 10 mM HEPES and 1% v/v PS). For the 96-well format concentration-response assay, T24 ps 2087 GS cl. 1D3 cells were seeded at a density of 6000 cells per well in black 96-well Packard Viewplates (PerkinElmer Inc., Boston, MA) and incubated O/N at 37 °C in a CO 2 incubator. The assays were initiated by adding 400× concentrated test compounds diluted in assay buffer (DMEM containing 10 mM HEPES and 1% v/v PS); 0.25% DMSO (Sigma) was used as negative control (S 0 ), and 10 µM UO126 (1,4-diamino-2,3-dicyano-1,4-bis (2-aminophenylthio)butadiene) (Calbiochem, La Jolla, CA) was used as the positive control (S max ). The final serum concentration in the assay was 5%. Cells were then incubated for 1 h at 37 °C in a CO 2 incubator before being fixed with 4% formalin buffer (VWR International, Westchester, PA), washed 3× in phosphate-buffered saline (PBS; Invitrogen), and stained with 0.5 µM DRAQ5 (BioStatus, Leicestershire, UK) in PBS for at least 30 min before being read on the INCell 3000 Analyzer (GE Healthcare, Buckinghamshire, UK).
Rev and NFATc1 Redistribution ® assays
BHK ps 1883 GS and U2OS ps 1513B GS cl. 1F9 cells were seeded at a density of 6000 cells per well in black 96-well Packard Viewplates and incubated O/N at 37 °C in a CO 2 incubator. The assays were initiated by adding 400× concentrated test compounds diluted in assay buffer (i.e., DMEM, 5 mM HEPES, and 1% PS); 0.25% DMSO was used as the negative control (S 0 ). Then, 50 nM Ratjadone (Alexis Corporation, Lausen, Switzerland) was used as the positive control (S max ) in the Rev assay. Cells were incubated for 1 h at 37 °C in a CO 2 incubator before fixation with 4% formalin buffer, washed 3× in PBS, stained with 0.3 µM DRAQ5, and read on the INCell 3000 Analyzer. Then, 0.3 µM FK506 was used as the positive control (S max ) in the NFATc1 assay. In the NFATc1 assay, cells were preincubated with controls and test compounds for 1 h at 37 °C in a CO 2 incubator before addition of 1 µM ionomycin (Calbiochem) for 5 min. The cells were then fixed with 4% formalin buffer, washed 3× in PBS, stained with 0.3 µM DRAQ5, and read on the INCell 3000 Analyzer.
INCell procedure
All assay plates were read on the INCell 3000 Analyzer. The instrument was equipped with a 40× dry objective and a 488-nm EGFP excitation filter, a 633-nm DRAQ5 excitation filter, a 535-nm/45-nm bandwidth EGFP emission filter, and a 695-nm/ 55-nm DRAQ5 emission filter. Neutral density filters were applied when appropriate. The plates were exposed for 1.5 ms at a binning of 2. The scan width and length were 0.745 nm and the slit width 30 µm. The INCell 3000 Trafficking analysis module (BIO1) was used in all Redistribution ® assays to monitor nucleocytoplasmic localization. The BIO1 algorithm is designed to extract nuclear and cytoplasmic EGFP intensity values and is based on defining cells using the DRAQ5-stained nuclei. The capability of DRAQ5 to stain the cytoplasm of cells, although with a lower affinity than for the nuclei, is used in the BIO1 algorithm to define the cytoplasm. The EGFP fluorescence intensity in the nuclei and cytoplasm can then be measured by using the BIO1 analysis parameters. On average, approximately 200 cells (range, 150-300 cells/ image) were analyzed from each image. The logarithm of the nuclear/cytoplasmic ratio was calculated for each well by the algorithm and taken as a measurement of the nuclear-to-cytoplasmic translocation of EGFP.
Redistribution

® assay data analyses and calculations
Data were only accepted if the Z´ factor 16 was ≥ 0.3. For each individual plate, the average raw activity and SD were calculated for the negative control, S 0 , and the positive control, S max (8 wells of each on every 96-well plate, 24 wells of each on every 384-well plate). The Z´ factor was calculated from the S 0 and S max raw activity according to the following formula:
). Activity (%) for each well was calculated relative to the positive control (S max ) from the raw activity: Activity (%) = 100*(Sample − S 0 )/(S max − S 0 ). For concentrationresponse determinations, a concentration-response curve was fitted to the activity (%) values using GraphPad Prism 3.03 Software (GraphPad Software Inc., San Diego, CA), and, if possible, an EC 50 value was extracted.
Alamar Blue cell proliferation assay
Human prostate adenocarcinoma cancer (PC3) cells and malignant melanoma (WM-266-4) cells were plated in clear 96-well plates in growth medium (100 µL/well) at a cell density of 5000 and 4000 cells/well for WM-266-4 and PC3, respectively. The cell densities were selected so that the cells reached 90% confluency during 3 days of normal growth. The day after plating, the growth medium was changed to assay medium consisting of RPMI supplemented with 1% (v/v) FBS (BioChrom AG), 1% (v/v) penicillin-streptomycin (Invitrogen/ Gibco), and 25 µg/mL gentamicin (Invitrogen/Gibco). Compounds were dissolved in DMSO, diluted in assay medium, and added to the cell plates by transfer of 100 µL/well, resulting in a total volume of 200 µL/well containing a final concentration of 0.25% DMSO and appropriate compound concentrations. Terfenedine (Sigma-Aldrich) was used as a positive control in wells containing 50 µM terfenedine and 1% DMSO (S max ). Negative control wells (S o ) contained medium with 0.25% DMSO. After compound addition, cell plates were incubated undisturbed for 72 h at 37 °C, 5% CO 2 , and 95% humidity. The number of viable cells was estimated using an Alamar Blue assay. The medium was decanted and replaced with 150 µL/ well RPMI medium without phenol-red containing 1% (v/v) penicillin-streptomycin and 10% Alamar Blue. The plates were placed in the incubator at 37 °C, 5% CO 2 , and 95% humidity for 2 h. Plates were then allowed to cool to room temperature without stacking. Alamar Blue signal was read in a fluorescence plate reader (SPECTRAFluor Plus, Tecan, Männedorf, Switzerland) using a 590-nm emission filter and a 530-nm excitation filter. Data handling/calculations were the following: data were normalized to values from 0% activity (S 0 ) to 100% activity (S max ). Average values for S 0 and S max were calculated and used to calculate percentage activity (PCTACT) in the assays by the following formula: PCTACT = (X raw -S max )/(S 0 -S max )*100. Sigmoidal curve fitting was done in Prism using the following equation: Y = Bottom + (Top − Bottom)/[1 + 10^((log EC 50 − X)*HillSlope)].
Cell proliferation inhibition by ERK siRNA transfection
WM-266-4 and PC3 cells were seeded as described previously with the following modifications: 6-well plates at a volume of 2 mL/well and a cell density of 1. Cells were then subjected to three 5-min washes in PBS containing 1% BSA and 2 final washes in PBS. Immunofluorescence staining was analyzed using an INCell Analyzer 3000 (GE Healthcare).
Western blot analysis
WM-266-4 cells were seeded at a density of 4.0 × 10 5 cells/well in 6-well plates and incubated for 24 h at 37 °C, 5% CO 2 , and 95% humidity. On the day of the experiment, cells were treated for 1 h at 37 °C, 5% CO 2 , and 95% humidity, in the presence or absence of the appropriate compounds and controls. Samples from treated cells were prepared and immunoblotted as described previously by Lundholt et al. 17 The primary antibodies used were B-RAF (SC-5284; diluted 1:3000) and C-RAF (RAF-1), and C-12 (SC-133; diluted 1:500) from Santa Cruz Biotechnology or MEK1/2 (#9122; diluted 1:2000), p44/42 MAP kinase antibody (#9102; diluted 1:1000), and phospho-p44/42 MAP kinase (Thr202/Tyr204) (#9101; diluted 1:1000) or the Pathscan ® Multiplex Western Cocktail I (diluted 1:1000) in blocking buffer from Cell Signaling Technology (Beverly, MA). This cocktail simultaneously detects levels of phospho-p90RSK, phospho-Akt, phospho-p44/42 MAPK (ERK1/2), and phospho-S6 ribosomal protein and also contains an eIF4E antibody to monitor protein loading.
pERK ELISA
WM-266-4 cells were seeded at a density of 4.0 × 10 5 cells/well in 96-well microplates (Nunc, Roskilde, Denmark at volume of 100 µL culture medium and incubated for 24 h at 37 °C, 5% CO 2 , and 95% humidity. On the day of the experiment, test compounds and controls were diluted to appropriate concentrations in culture medium and added to the cells at a volume of 100 µL. The cells were treated for 1 h at 37 °C, 5% CO 2 , and 95% humidity. Samples for the ERK1/2 [pTpY185/ 187] phospho ELISA (Biosource International, Camarillo, CA) were prepared as follows: culture medium was gently aspirated using an 8-channel VacuBoy pipette attached to a vacuum flask with waste reservoir. Extraction buffer (prepared according to the manufacturer's instructions with the exception of PMSF being substituted with 300 µM 4-(2-Aminoethyl)-bezenesulfonylfluoride [AEBSF, Calbiochem, Nottingham, UK]) was added at 50 µL/ well. The samples were incubated for 20 min at room temperature on a rotating shaker plate. The total lysate was denatured by transferring the complete lysate to a 96-well Thermo-Fast PCR plate and incubated for 15 min at 100 °C in a Thermo cycler. The PCR plate was subsequently centrifuged for 5 min at 750g at room temperature. The samples were diluted 30 times in dilution buffer (supplied in ELISA kit), and 100 µL was added to the ELISA plate. The ELISA procedure was performed according to the manufacturer's instructions. The plate was read on an absorbance plate reader, and a standard curve was used to transform absorbance values into units/mL. The pERK ELISA data were analyzed by nonlinear regression analysis using GraphPad Prism 3.03 Software (GraphPad Software).
In vitro kinase inhibition assays
The inhibitory activities of compounds at 1 and 10 µM against human EGFR, MEK1, c-RAF, MAPK1, and MAPK2 kinases were determined by Upstate Ltd. (Dundee, UK), as described in the assay protocols on the Upstate Web page (www.upstate.com/features/kp_protocols.asp).
RESULTS
Identification of MAPK pathway inhibitors by an ERF1 Redistribution ® high-throughput screen
To identify compounds that inhibit the MAPK signaling pathway downstream of RAS, we developed a high-throughput ERF1 Redistribution ® assay for screening a diverse smallmolecule library of 265,623 compounds (average Tanimoto constant < 85%). This assay measures the nuclear-to-cytoplasmic ratio of EGFP-ERF1 and identifies compounds that promote nuclear retention of ERF1 as a surrogate for pathway inhibition. The assay was developed as a 384-well format screening assay to be read and analyzed on an InCell Analyzer 3000. An EGFP-ERF1 fusion protein was stably transfected into the human transitional cell carcinoma bladder cell line (T24). T24 cells contain an activating H-RAS mutation, causing constitutive activation of the MAPK pathway 18 and resulting in a predominantly cytoplasmic localization of EGFP-ERF1. EGFP-ERF1 nuclear retention is induced by known pathway inhibitors such as the MEK1/2 inhibitor U0126, 19 as depicted in the schematic description of the assay in Figure 1A . In the ERF1 Redistribution ® assay, U0126 is used as the reference compound to determine maximal activity in the assay, and the degree of inhibition by a compound is calculated as percentage activity (PCTACT) relative to the U0126 control. The expression of the pathway components between RAS and ERF1 (B-RAF, MEK1/2, ERK1/2) was confirmed with Western blot analysis on whole-cell lysates from the screening cell line (Fig. 1B) . C-RAF expression was also detected (data not shown). Pathway inhibition by the MEK inhibitor U0126 was also confirmed by phospho-ERK1/2 Western blot analysis on whole-cell lysates from cells treated with compound (Fig. 1B) .
Library compounds were tested at 10 µM, and compounds with an activity above 25% in the screening assay were scored as positives. The cutoff of 25% was selected to reduce the number of false-positive hits and was determined after running a test screen with 6 plates containing compounds representative for the library composition as well as 2 plates with known fluorescent and toxic compounds. When screening the complete library, 1739 compounds were positive, yielding an initial hit rate of 0.65% ( Table 1 ). The distribution of hits according to their activity is shown in Figure 2A . The average Z' factor of the 844 plates screened was 0.62 (Fig. 2B) . The activity in the screening assay (as measured by a change in the nuclear-to-cytoplasmic fluorescence ratio) can be due to 3 unrelated phenomena: 1) an increase in the nuclear/cytoplasmic fluorescence ratio of EGFP-ERF1 (a real hit), 2) fluorescence of a compound, and 3) toxicity of a compound resulting in cell rounding. In addition to reporting the nuclear-to-cytoplasmic fluorescence ratios, the imaging algorithm is designed to calculate auxiliary values used to quantify cell rounding and fluorescence. This allowed for an automated deselection of most artifacts such as fluorescent and toxic compounds. In total, 250 compounds were deselected because of cell toxicity and 76 compounds because of intrinsic fluorescence ( Table 1) .
The chemical quality of this initial hit set was improved by computational filtering using an in-house computer filter based on the Lipinski rules that removes frequent hitters and nondrug-like structures such as unstable compounds and those with undesirable physicochemical properties. 20 This filtering process and a subsequent manual inspection of the chemical structures to remove compounds not caught by the computer filter removed 700 compounds from the hit set ( Table 1 ). The remaining 731 compounds were evaluated with reference to chemical diversity using computational methods (principal component analysis based on 66 orthogonal descriptors). Furthermore, the use of an image-based screening platform also allowed for a 2nd deselection of remaining fluorescent and toxic compounds based on a visual examination of the images. Thirty-one compounds were removed after visual inspection of the images, leaving 718 compounds for retest, resulting in a final hit rate in the screen of 0.27% (Table 1) . Retest of compounds identified in the ERF1 Redistribution ® high-throughput screen
RAS-MAPK Signaling
The 718 hits identified in the screen were retested in the ERF1 Redistribution ® assay at 12.5 µM in 3 independent experiments. In total, 522 compounds with an average retest activity below 20% were deselected, as well as 8 additional fluorescent compounds ( Table 1) . The 718 compounds were also tested at 12.5 µM in 3 independent experiments in a Rev Redistribution ® assay and in a WM-266-4 melanoma cell proliferation assay. The Rev Redistribution ® assay is used to detect nonspecific inhibition of Crm1-mediated export. 21 Rev continuously shuttles between the nucleus and cytoplasm, and upon inhibition of nuclear export, Rev accumulates in the nucleus. Ratjadone A, a nonspecific inhibitor of Crm1-mediated nuclear export, was used as the positive control in this assay, 22 with an IC 50 value of approximately 4.5 nM (data not shown). Overall, 52 compounds with an ERF1-to-Rev assay activity ratio between 0 and 2 were considered nonselective export inhibitors and were deselected ( Table 1) . The WM-266-4 cell line is a malignant melanoma cell line expressing oncogenic B-RAF, 23 which was selected as a disease-and pathway-relevant functional assay to identify compounds that selectively inhibit proliferation of cells with a hyperactive MAPK signaling pathway. The line was tested for pathway sensitivity with a selective control pathway inhibitor (U0126), 24 as well as with ERK1/2 siRNA. U0126 inhibited WM-266-4 proliferation with an IC 50 of 0.9 µM (Fig. 3A) . Furthermore, transfection with ERK2 siRNA inhibited cell proliferation by 80%, confirming that inhibition of proliferation was caused by MAPK pathway inhibition (Fig. 4A) . Western blot analysis showed that ERK2 protein was knocked down by the siRNA transfection (Fig. 4B) . No ERK1 protein knockdown or inhibition of cell proliferation was seen following ERK1 siRNA transfection (Fig. 4A,B) , showing that ERK2 knockdown is sufficient to yield pathway inhibition in this cell line. Eighty-four compounds with an average activity below 20% in the cell proliferation assay were considered inactive in the functional assay and were not progressed further ( Table 1) .
Identification of compound that selectively inhibits proliferation of MAPK pathway-dependent cells
Fifty-one compounds (0.02% of the screened compounds) were confirmed as positive in the ERF1 Redistribution ® assay (> 20% activity), inactive in the Rev Redistribution ® assay, and inhibited proliferation of pathway-dependent WM-266-4 cells (> 20% activity) ( Table 1) . These compounds were progressed for concentration-response studies in the pathway-relevant cell proliferation assay. At this stage, inhibitory activity in the pathway-dependent WM-266-4 cell line was compared with the activity in a pathway-independent cell line. The human bone adenocarcinoma prostate cancer cell line (PC3) was 20-fold less sensitive to U0126 (Fig. 3A) and was selected as the pathway-independent cell line. The WM-266-4 and PC3 cells were analyzed by Western blotting to evaluate MAPK pathway activation status (data not shown). These studies confirmed both the expression of relevant pathway components in WM-266-4 cells and that reference pathway inhibitors such as U0126 reduced pathway activity in the WM-266-4 cell line. The phospho-ERK1/2 analysis also confirmed the absence of phospo-ERK1/2, and hence MAPK pathway activity, in the PC3 cell line.
Two compounds were shown to be more than 2-fold selective in the functional cell proliferation assays. SCR0046115 inhibited proliferation of WM-266-4 and PC3 cells with an IC 50 of 2.5 µM and a maximum activity of 78%, as well as an IC 50 of 5.6 µM and a maximum activity of 77%, respectively (Fig. 3B) . SCR0146726 inhibited proliferation of WM-266-4 and PC3 cells with an IC 50 of 1.3 µM and a maximum activity of 71%, as well as an IC 50 of 5.3 µM and a maximum activity of 25%, respectively (Fig. 3C) . Forty-nine compounds were less than 2-fold selective in the cell proliferation assays and therefore not progressed further. Immunostaining of ERF1 in WM-266-4 cells showed that SCR0046115 (Fig. 5A ) and SCR 0146726 (Fig. 5B) , as well as the control pathway inhibitor U0126 (Fig. 5C) , induced nuclear accumulation of endogenous ERF1. In untreated WM-266-4 cells, ERF1 was mostly located in the cytoplasm (Fig. 5D) , as expected based on the constitutive ERK pathway activity in this cell line.
Concentration-response determinations in Redistribution ® assays
Concentration-response determinations demonstrated that the IC 50 of SCR0046115 in the ERF1 Redistribution ® assay was 1.3 µM with a maximum activity of 100% (Fig. 3E) . The IC 50 of SCR0146726 in the ERF1 Redistribution ® assay was 2.8 µM with a maximum activity of 101% (Fig. 3F) . By comparison, the IC 50 of the reference inhibitor U0126 was 0.3 µM with a maximum activity of 107% (Fig. 3D) . Visual inspection of images from the INCell 3000 Analyzer confirmed that SCR0046115 and SCR0146726 induced nuclear accumulation of EGFP-ERF1 to the same degree as U0126 (Fig. 6A-D) and that all 3 compounds were inactive in the Rev Redistribution ® assay (Figs. 3D-F and 6E-H) , confirming that the hit compounds were not general inhibitors of Crm1-mediated nuclear export. An NFATc1 Redistribution ® assay, which monitors the translocation of an EGFP-NFATc1 fusion protein from the cytoplasm to the nucleus, was also used to evaluate compound effects on the nuclear import process. NFATc1 is a transcription factor that resides in the cytosol and translocates to the nucleus in response to elevated calcium levels. 25 Ionomycin was used as the reference agonist, and compounds were assayed for their ability to inhibit ionomycin-induced translocation. FK506 was used as a reference inhibitor. 25 The IC 50 value of FK506 in the assay was approximately 2 nM (data not shown). Both SCR0046115 and SCR0146726, as well as U0126, were negative in the NFATc1 Redistribution ® assay (Figs. 3D-F and 6I-L) , suggesting that inhibition of ERK1/2
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Compound effect on ERK phosphorylation and pathway kinases
SCR0046115 and SCR0146726 were shown to inhibit ERK phosphorylation in a phospho-ERK ELISA assay with IC 50 values of 0.8 µM and 1.1 µM, respectively (Fig. 7A) . U0126 inhibits ERK phosphorylation with an IC 50 of 0.3 µM in the same assay (Fig. 7A) . Phospho-ERK1 and 2 inhibition was also confirmed by Western blot analysis (Fig. 7B) . These data confirm that SCR0046115 and SCR0146726 act by inhibiting the MAPK pathway and show that they are acting at the level of, or upstream of, ERK1/2. This is consistent with a mode of action that is separate from interfering with the nuclear transport machinery. Further characterization of the hit compounds in the in vitro kinase assays showed that SCR0046115 and SCR0146726 did not inhibit human EGFR, C-RAF, ERK1, ERK2, and MEK1 (Upstate Ltd., Dundee, UK) at compound concentrations of 1 µM or 10 µM, except for a minor inhibitory activity of ERK1 ( Table 2 ). These data show that SCR0046115 and SCR0146726 are unlikely to act in the pathway by kinase inhibition. 
DISCUSSION
Data are presented as mean ± SD from 2 determinations.
localization of proteins, either causally or diagnostically. 26 The Redistribution ® technique allows the identification of compounds that modulate the translocation of proteins within the cell. Hence, the technique enables the discovery of compounds with novel modes of action, such as protein-protein interaction modulators, and also allosteric, noncatalytic site inhibitors. Redistribution ® assays have several advantages over traditional in vitro screening assays. They are cell-based assays and as such facilitate the discovery of drug-like structures possessing adequate solubility, membrane permeability, and stability in the intracellular environment. Furthermore, the assays are imagebased high-content assays that enable automatic deselection of compounds with potentially toxic effects that acutely alter cell morphology, in addition to fluorescent compounds. 20 Finally, Redistribution ® assays allow chemico-genomic probing of entire signaling pathways, thereby prioritizing the most powerful combination of compound and target. These key features serve to increase the quality of hit compounds and allow meaningful direct progression of compounds through functional characterization without further in vitro ADME/Tox studies. High-content screening assays also have certain disadvantages, including the need for specialized personnel and expensive equipment (see Lundholt et al 17 for discussion), and traditional cell-based assays for cancer drug discovery, such as tumor cell proliferation assays, may also allow the discovery of tumor-selective compounds. However, it is often difficult to find relevant control cell lines as most tumor cell lines have different growth characteristics from corresponding normal cells. Even in cases where a relevant control cell line exists, selectivity may be difficult to address in a screening setting, where each compound is tested at only 1 concentration. In addition, any given cancer cell line may have acquired multiple mutations, some of which may be relatively rare. When screening for inhibitors of a specific cancer cell line, one might therefore find compounds with many different modes of action, a number of which may target lesions occurring only in a very limited set of cancers. To circumvent some of these shortcomings, Torrance et al 27 derived a control cell line from an existing colorectal cancer cell line by deleting the activated K-RAS gene using homologous recombination. By labeling the parental cancer cell line and the K-RAS deleted line with different fluorophores, it was possible to screen for compounds preferentially targeting the RAS-transformed cancer cell line. However, this kind of approach is only applicable when the lesion one wishes to target is not essential to the proliferation of the cancer cell line and would probably not have worked with the melanoma cell line used in the present study. Furthermore, hit compounds are unlikely to target a nonessential pathway. It is therefore likely that the selective compounds described by Torrance et al 27 target a pathway that is required for the cell to cope with elevated RAS activity, rather than the RAS pathway itself. Although this kind of approach is interesting from a chemical genomics point of view, it does require substantial work postscreening to determine compound mode of action to secure biomarkers for preclinical and clinical development. Finally, the difficulty in assessing selectivity based on single-point determination of compound activity, coupled with the high hit rate (~6%) reported by Torrance et al, results in the necessity for extensive cherry-picking and compound profiling in a concentrationresponse format. 27 To overcome the difficulties in picking the right compounds for progression through the development pipeline, we reasoned that the best solution is to target a relevant signaling pathway using a cell-based assay such as a Redistribution 
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® assays directed at distinct signaling pathways or at different intersection points within a specific pathway then ensures identification of highly selective compounds and aids the initial delineation of the mode of action. 17, 21 The MAPK pathway is a key regulator of cellular proliferation. Several proteins in this pathway are known as relevant targets for cancer therapy, and a number of drugs inhibiting this pathway are already in preclinical or clinical development. 3, 14, 28 Perhaps owing to the fact that mutations in the RAS proteins are among the most frequently encountered genetic abnormalities in human cancers, 2, 29 RAS has been targeted in a number of different ways, including antisense or ribozyme approaches, 30 small-molecule RAS endoprotease inhibitors, 31 farnesyltransferase inhibitors, 32 and RAS/RAF protein-protein interaction inhibitors. 33 Of these, the farnesyltransferase inhibitors are by far the most advanced, with tipifarnib (R-115777; Zarnestra) currently undergoing phase III testing against acute myeloid leukemia. However, as the effect of farnesyltransferase inhibitors is not mediated exclusively through RAS inhibition, 34 the potential clinical benefits of selective RAS inhibition remain largely unexplored. RAF proteins constitute another promising target in the MAPK pathway as gene mutations, especially B-RAF mutations, have also been associated with human cancers. 23 One existing RAF inhibitor is the adenosine triphosphate (ATP)-competitive pan-RAF kinase inhibitor sorafenib (BAY 43-9006), which has been shown to be a potent inhibitor of colon, pancreatic, melanoma, and other tumor types. 3, 35, 36 Sorafenib is now in clinical phase III testing in multiple tumor types. However, as the compound inhibits multiple other kinases, including the PDGFR-beta and VEGFR-2 receptor tyrosine kinases, it is conceivable that the clinical effect observed in sorafenib trials derives, at least in part, from effects on tumor vasculature rather than from direct inhibition on tumor cell proliferation. 37 Therefore, clinical validation of the RAF family as oncology targets will await the development of more specific inhibitors. A C-RAF-directed antisense oligonucleotide is currently in clinical phase I testing and may provide a 1st indication on the validity of targeting single RAF kinase isoforms. 38 Several MEK kinase inhibitors have also been developed, including CI-1040 (PD184352), 39 U0126, 19 and PD325901. Data from studies with CI-1040 suggest that cancer cells such as pancreatic, colon, melanoma, and mammary carcinomas can be treated with MAPK pathway inhibitors. The structurally very similar and more potent PD325901 is currently undergoing clinical phase I/II evaluation in patients with advanced tumors. 40, 41 One additional MEK inhibitor, ARRY-142886, was recently advanced into clinical phase I trials. 41 As both PD325901 and ARRY-142886 are highly selective, noncompetitive inhibitors of MEK kinases, full clinical validation of MEK as a cancer target will be forthcoming. No selective inhibitors of ERK1 or 2 have been reported today, but knockdown of ERK2 in pathway-activated melanoma cells results in drastically reduced levels of proliferation, suggesting that ERK2 may also be a valid therapeutic target if sufficiently selective inhibitors could be developed (Fig. 4A) .
We have used a Redistribution ® assay monitoring the membrane-distal target ERF1 to screen for compounds that act at various levels of the MAPK pathway. A total of 265,623 compounds were assayed in high throughput for their ability to localize ERF1 to the nucleus. Positive compounds were tested in a disease-relevant, pathway-specific cell proliferation assay to identify functional MAPK pathway modulators. The validity of this approach was confirmed with known pathway kinase inhibitors in combination with siRNA studies. In the ERF1 Redistribution ® screen, we were able to obtain a low hit rate (0.65%) compared to similar types of screens. 17, 21, 42 This may be due to the design of the assay. The ERF1 Redistribution ® assay was developed in T24 cells, which harbor an activating H-RAS mutation, causing spontaneous activation of the MAPK pathway. 18 Hence, hit compounds most likely act downstream of RAS, which leaves a defined part of the pathway with few possible intervention points (i.e., RAF, MEK, ERK, and ERF1) as the potential targets for pathway inhibition. It should be noted that the low hit rate may also be due in part to the composition of the compound library. The low hit rate may also explain why the hit confirmation rate was somewhat lower than what we normally encounter when screening Redistribution ® assays (our confirmation rates are normally approximately 50%; data not shown). Assuming that compound activity follows a normal distribution, a certain number of compounds (false positives) will be scored as hits during a screen based on pure statistics. When an assay yields a lower than normal hit rate, as is the case here, the number of false positives due to statistics will assume a relatively greater fraction of the initial hit set. In the cell proliferation assay, all compounds with an average activity below 20% in the pathway hyperactive cell line were considered inactive and not progressed to concentrationresponse determination in the 2 cell lines, even though they may have been cell line selective ( Table 1) . This deselection was made to reduce the number of hit compounds progressed to those with activities in the low micromolar range to facilitate chemical optimization of the compounds. Hence, only 2 of the 51 hit compounds confirmed as positives in the ERF1 screen were selective in the functional cell proliferation assay. It should also be noted that the cell proliferation assay is an assay that runs over 3 days, and it is possible that only very stable compounds will be active in this assay as compared to the ERF1 Redistribution ® assay. Finally, compounds that increase the GTPase activity of mutant RAS or inhibit the interaction between RAS and RAF may be negative in the cell proliferation assay as the assay cell line is driven by an activating B-RAF mutation.
Our hit progression strategy may help explain why no RAF/MEK/ERK kinase inhibitors were detected, even though the assay can detect inhibitors of pathway kinases (e.g., U0126), and our compound library should contain kinase inhibitors as no effort has been made to eliminate them from the library. Only compounds that were positive in the screening assay and positive and selective in the cell proliferation assay and, at the same time, negative in the Rev and NFATc1 assays were subjected to kinase activity testing. However, it remains entirely possible that any of the 186 remaining confirmed hits inhibit 1 or more kinases in the pathway but failed in 1 or more of the secondary tests due to parameters such as selectivity (inhibition of kinases outside the MAPK pathway might result in equal killing of PC3 cells) or chemical stability (unstable compounds might not show activity in a prolonged assay such as the cell proliferation assay).
One of the 2 novel MAPK pathway inhibitors found in this screen is SCR0146726 (dimethyl-carbamic acid 3-(4-fluoro-benzyl)-4-methyl-2-oxo-2H-chromen-7-yl ester), which belongs to a class of coumarine structures ( Table 2) . The structurally most similar compounds being used as drugs include warfarin and derivatives thereof. The 2nd compound is SCR0046115 (acetic acid 6-methoxy-3,3-dimethyl-2-thiophen-2-yl-1,2,3,4-tetrahydro-quinolin-4-yl ester), which is a drug-like compound that shows only minor structural similarities to other known drugs. These compounds exhibit ERF1 Redistribution ® assay activity in the low micromolar range and selectively inhibit the proliferation of MAPK pathway-dependent malignant melanoma cells with similar potencies. These data suggest both that antiproliferative activity is due to pathway inactivation and that the compounds might inhibit growth of tumors with aberrations in the pathway with low general cell toxicity. They are inactive in the Rev Redistribution ® assay, which identifies general inhibitors of nuclear export, and in the NFATc1 Redistribution ® assay, which monitors nuclear import, suggesting that these compounds do not act by inhibition of ERF1 or ERK1/2 nuclear transport. Their ability to inhibit phosphorylation of ERK1/2 indicates that they act upstream of ERK1/2 or interfere with ERK phosphorylation at the level of ERK itself. Because the compounds also have activity in assays driven by activated RAS or RAF, they would be expected to inhibit 1 or more components of the central RAF-MEK-ERK cassette. However, the compounds were shown to be negative in RAF, MEK, and ERK in vitro kinase assays, suggesting that they have hitherto undescribed modes of action. Both compounds have drug-like structures but are not chemically related, suggesting that they may act in different ways. However, further experiments using, for example, an affinity-chromatography approach or a phenotypic screening approach are needed to delineate the exact mechanism of action of the compounds.
In conclusion, we have performed a high-content screen in high throughput with the distal MAPK effector ERF1 in a Redistribution ® assay and found compounds that selectively inhibit proliferation of cells with a hyperactive MAPK pathway. Drugs belonging to these compound classes may prove useful for treating cancers caused by MAPK pathway aberrations, and delineation of their precise mode of action may reveal novel therapeutic targets in this disease-relevant pathway. The data presented also show that cell-based high-content screens, when conducted in defined systems, can complement traditional in vitro target-based and functional cell-based screens and aid identification of drug-like, cell-permeable compounds with low general cell toxicity that act by novel modes of action.
